Oversight of Genetic Testing

In June, as the public and private genome projects prepared to announce the rough mapping of the human genome, a special Department of Health and Human Services (HHS) genetics ethics committee was wrapping up its own report on how the government should oversee genetic testing. In the report, sent to assistant secretary and surgeon general David Satcher, the Health and Human Services Secretary's Advisory Committee on Genetic Testing, or SACGT, recommends that the government provide additional ove

Written byDave Amber
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In June, as the public and private genome projects prepared to announce the rough mapping of the human genome, a special Department of Health and Human Services (HHS) genetics ethics committee was wrapping up its own report on how the government should oversee genetic testing. In the report, sent to assistant secretary and surgeon general David Satcher, the Health and Human Services Secretary's Advisory Committee on Genetic Testing, or SACGT, recommends that the government provide additional oversight on genetic tests and that the Food and Drug Administration take the lead in approving all new genetic tests. "The American people want to see that they can trust a test," says Edward McCabe, chairman of the SACGT and professor of pediatrics at the University of California, Los Angeles. "We want to see that there is a positive impact on medical care."

Privacy in the age of genetic tests remains a thorny issue. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies